ARWR
Arrowhead Pharmaceuticals Inc.
$60.36
-$0.68(-1.11%)
36
Overall
30
Value
36
Tech
42
Quality
Market Cap
$4.90B
Volume
817.54K
52W Range
$9.57 - $76.76
Target Price
$81.67
Order:
Income Statement
| Metric | Trend | Chart | 2016 Sep | 2017 Sep | 2018 Sep | 2019 Sep | 2020 Sep | 2021 Sep | 2022 Sep | 2023 Sep | 2024 Sep | 2025 Sep |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $158.3K | $31.4M | $16.1M | $168.8M | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M | ||
| Total Revenue | $158.3K | $31.4M | $16.1M | $168.8M | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $158.3K | $31.4M | $16.1M | $168.8M | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $74.1M | $-68.4M | $-72.1M | $107.6M | $181.2M | $287.3M | $421.7M | $445.7M | $604.6M | $731.1M | ||
| Research & Development | $41.5M | $50.9M | $53.0M | $81.0M | $128.9M | $206.3M | $297.3M | $353.2M | $505.9M | $607.2M | ||
| Research Expense | $41.5M | $50.9M | $53.0M | $81.0M | $128.9M | $206.3M | $297.3M | $353.2M | $505.9M | $607.2M | ||
| Selling, General & Administrative | $9.9M | $17.5M | $19.1M | $26.6M | $52.3M | $81.0M | $124.4M | $92.5M | $98.8M | $123.9M | ||
| General & Administrative Expenses | $9.9M | $17.5M | $19.1M | $26.6M | $52.3M | $81.0M | $124.4M | $92.5M | $98.8M | $123.9M | ||
| Salaries & Wages | $19.5M | $25.2M | -- | -- | -- | -- | -- | -- | $67.1M | $54.8M | ||
| Depreciation & Amortization | $3.3M | $-3.0M | $-3.0M | $2.7M | $4.2M | $6.6M | $8.7M | $10.7M | $16.9M | -- | ||
| Depreciation & Amortization | $3.3M | $-3.0M | $-3.0M | $2.7M | $4.2M | $6.6M | $8.7M | -- | -- | -- | ||
| Amortization | $-1.7M | $-1.7M | $-1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $9.8M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-74.0M | $-37.0M | $-55.9M | $61.2M | $-93.2M | $-149.0M | $-178.5M | $-205.0M | $-601.1M | $98.3M | ||
| EBITDA | $-66.9M | $-29.7M | $-49.7M | $72.6M | $-87.2M | $-132.6M | $-162.3M | $-175.7M | $-561.5M | $164.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | $18.3M | $32.4M | $89.4M | ||
| Intinc | $265.8K | $415.1K | $1.0M | $7.0M | $9.2M | $6.1M | $5.0M | $15.3M | $22.7M | $37.3M | ||
| Net Non-Operating Interest Income/Expense | $265.8K | $415.1K | $1.0M | $7.0M | $9.2M | $6.1M | $-5.0M | $-3.0M | $-9.6M | $-52.1M | ||
| Gain on Sale of Securities | $-301.0K | $890.4K | $432.1K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-5.6M | $-2.2M | $-439.6K | $-22.4M | $583.0K | $-2.1M | $765.0K | $-1.5M | $1.7M | $-5.3M | ||
| Other Special Charges | $57.4K | $1.3M | $7.5K | $22.4M | $-583.0K | $2.1M | $5.8M | $1.5M | $-1.7M | $5.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | $-90.3M | $-279.0M | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-2.1M | -- | -- | $90.3M | $279.0M | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | $2.1M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-70.1M | $-34.4M | $-54.4M | $68.1M | $-93.2M | $-140.8M | $-172.7M | $-188.2M | $-580.1M | $140.9M | ||
| Pre-Tax Income | $-70.1M | $-34.4M | $-54.4M | $68.1M | $-84.6M | $-140.8M | $-172.7M | $-206.5M | $-612.5M | $51.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $2.4K | $2.4K | $2.4K | $173.6K | $2.0K | $2.0K | $3.8M | $2.8M | $-2.8M | $21.4M | ||
| NET INCOME | ||||||||||||
| Net Income | $-81.7M | $-34.4M | $-54.5M | $68.0M | $-84.6M | $-140.8M | $-176.1M | $-205.3M | $-599.5M | $-1.6M | ||
| Net Income (Continuing Operations) | $-81.7M | $-34.4M | $-54.5M | $68.0M | $-84.6M | $-140.8M | $-176.5M | $-209.3M | $-609.7M | $30.1M | ||
| Net Income (Discontinued Operations) | $-81.7M | $-34.4M | $-54.5M | $68.0M | $-84.6M | $-140.8M | $-176.1M | $-205.3M | $-599.5M | $-1.6M | ||
| Net Income (Common Stockholders) | $-81.7M | $-34.4M | $-54.5M | $68.0M | $-84.6M | $-140.8M | $-176.1M | $-205.3M | $-599.5M | $-1.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $51.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $74.1M | $-68.4M | $-72.1M | $107.6M | $181.2M | $287.3M | $421.7M | $445.7M | $604.6M | $731.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $61.1M | $73.9M | $83.6M | $93.9M | $100.7M | $103.7M | $105.4M | $106.8M | $119.8M | $133.8M | ||
| Average Shares Outstanding (Diluted) | $61.1M | $73.1M | $83.6M | $98.6M | $100.7M | $103.7M | $105.4M | $106.8M | $119.8M | $133.8M | ||
| Shares Outstanding | $74.2M | $74.8M | $92.2M | $95.7M | $102.8M | $104.5M | $106.0M | $107.4M | $124.4M | $143.0M | ||
| Basic EPS | $-1.34 | -- | $-0.65 | $0.72 | $-0.84 | $-1.36 | $-1.67 | $-1.92 | $-5 | $-0.01 | ||
| Basic EPS (Continuing Operations) | $-1.34 | -- | -- | $0.72 | $-0.84 | $-1.36 | $-1.67 | $-1.92 | $-5 | $-0.01 | ||
| Diluted EPS | $-1.34 | $-0.47 | $-0.65 | $0.69 | $-0.84 | $-1.36 | $-1.67 | $-1.92 | $-5 | $-0.01 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $0.69 | $-0.84 | $-1.36 | $-1.67 | $-1.92 | $-5 | $-0.01 | ||
| OTHER METRICS | ||||||||||||
| Excise Taxes | $11.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | $244.0M | $461.8M | $408.8M | $431.0K | $4.0M | $10.2M | $-31.7M | ||
| Other Gand A | $9.9M | $17.5M | $19.1M | $26.6M | $52.3M | $81.0M | $124.4M | $92.5M | $98.8M | $123.9M | ||
| Other Impairment Of Capital Assets | $-944.9K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | -- | $17.5M | $19.1M | $1.7M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | $-90.3M | $-279.0M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARWR | $60.36 | -1.1% | 817.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arrowhead Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW